| 臺大學術典藏 |
2012 |
KRAS Mutation Is a Predictor of Oxaliplatin Sensitivity in Colon Cancer Cells
|
Lin Y.-L.; JAU-YU LIAU; Yu S.-C.; Ou D.-L.; Lin L.-I.; Tseng L.-H.; Chang Y.-L.; Yeh K.-H.; Cheng A.-L. |
| 國立臺灣大學 |
2012 |
KRAS Mutation Is a Predictor of Oxaliplatin Sensitivity in Colon Cancer Cells
|
Lin, Yu-Lin; Liau, Jau-Yu; Yu, Shan-Chi; Ou, Da-Liang; Lin, Liang-In; Tseng, Li-Hui; Chang, Yih-Leong; Yeh, Kun-Huei; Cheng, Ann-Lii; 林亮音; 曾麗慧; 張逸良; 林育麟; 鄭安理; 葉坤輝; 歐大諒; 尤善琦; 廖肇裕 |
| 臺大學術典藏 |
2012 |
KRAS Mutation Is a Predictor of Oxaliplatin Sensitivity in Colon Cancer Cells
|
Yeh K.-H.; Cheng A.-L.; YIH-LEONG CHANG; Lin L.-I.; Tseng L.-H.; Yu S.-C.; Ou D.-L.; Liau J.-Y.; Lin Y.-L. |
| 臺大學術典藏 |
2020-03-05T12:22:25Z |
KRAS Mutation Is a Predictor of Oxaliplatin Sensitivity in Colon Cancer Cells
|
Liau J.-Y.; SHAN-CHI YU; Ou D.-L.; Lin L.-I.; Tseng L.-H.; Chang Y.-L.; Yeh K.-H.; Cheng A.-L.; Lin Y.-L. |
| 臺大學術典藏 |
2020-03-07T06:56:33Z |
KRAS Mutation Is a Predictor of Oxaliplatin Sensitivity in Colon Cancer Cells
|
Lin Y.-L.; Liau J.-Y.; Yu S.-C.; Ou D.-L.; Lin L.-I.; Tseng L.-H.; YIH-LEONG CHANG; Yeh K.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2021-01-28T01:06:39Z |
KRAS Mutation Is a Predictor of Oxaliplatin Sensitivity in Colon Cancer Cells
|
Lin Y.-L.; Liau J.-Y.; Yu S.-C.; Ou D.-L.; Lin L.-I.; Tseng L.-H.; Chang Y.-L.; KUN-HUEI YEH; Cheng A.-L. |
| 臺大學術典藏 |
2021-09-01T01:53:55Z |
KRAS Mutation Is a Predictor of Oxaliplatin Sensitivity in Colon Cancer Cells
|
Lin Y.-L.; Liau J.-Y.; Yu S.-C.; Ou D.-L.; Lin L.-I.; Tseng L.-H.; Chang Y.-L.; Yeh K.-H.; ANN-LII CHENG |
| 臺大學術典藏 |
2022-03-10T07:58:45Z |
KRAS Mutation Is a Predictor of Oxaliplatin Sensitivity in Colon Cancer Cells
|
Lin Y.-L.; Liau J.-Y.; Yu S.-C.; Ou D.-L.; Lin L.-I.; LI-HUI TSENG; Chang Y.-L.; Yeh K.-H.; Cheng A.-L. |
| 國家衛生研究院 |
2013-05 |
KRAS mutation status-stratified randomized phase II trial of GEMOX with and without cetuximab in advanced biliary tract cancer (ABTC): The TCOG T1210 trial
|
Chen, LT;Chen, JS;Chao, Y;Tsai, CS;Shan, YS;Hsu, C;Huang, SF;Tsou, HH;Lee, KD;Chiu, CF;Rau, KM;Ho, CL;Yu, MS;Taiwan Cooperative Oncology Group |
| 國立成功大學 |
2013-05-20 |
KRAS mutation status-stratified randomized phase II trial of GEMOX with and without cetuximab in advanced biliary tract cancer (ABTC): The TCOG T1210 trial
|
Chen, Li-Tzong; Chen, Jen-Shi; Chao, Yee; Tsai, Chang-Sung; Shan, Yan-Shen; Hsu, Chiun; Huang, Shiu-Feng; Tsou, Hsiao-Hui; Lee, Kuan-Der; Chiu, Chang-Fang; Rau, Kun-Ming; Ho, Ching-Liang; Yu, Ming-Sun |
